CD19 and precursor B-cell acute lymphoblastic leukemia: CD19 targeted CAR T-cell therapies have been successfully used in patients with B-cell hematological malignancies, and also demonstrated consistently high antitumor efficacy in the relapsed B-ALL, CLL and B-cell non-Hodgkin lymphoma (B-NHL) [151].